Jacques Montplaisir Dominique Petit Marie-Josée Quinn Manale Ouakki Geneviève Deceuninck Alex Desautels Emmanuel Mignot Philippe De Wals
10.1371/journal.pone.0108489
PLoS One
2014 Sep 29;9(9):e108489.
CC BY
https://pubmed.ncbi.nlm.nih.gov/25264897/
Adjuvants, Immunologic / adverse effects Influenza Vaccines / adverse effects Influenza, Human / prevention & control Narcolepsy / epidemiology Polysorbates / adverse effects Squalene / adverse effects alpha-Tocopherol / adverse effects
Adjuvants, Immunologic / adverse effects Influenza Vaccines / adverse effects Influenza, Human / prevention & control Narcolepsy / epidemiology Polysorbates / adverse effects Squalene / adverse effects alpha-Tocopherol / adverse effects Research Support, Non-U.S. Gov't Adolescent Adult Case-Control Studies Child Drug Combinations Female Humans Influenza A Virus, H1N1 Subtype / immunology Influenza Vaccines / therapeutic use Influenza, Human / immunology Male Middle Aged Polysorbates / therapeutic use Quebec / epidemiology Retrospective Studies Squalene / therapeutic use Vaccination Young Adult alpha-Tocopherol / therapeutic use Adjuvants, Immunologic Drug Combinations Influenza Vaccines Polysorbates Squalene AS03 adjuvant alpha-Tocopherol
PMC4180737
25264897
Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec
2014